Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

SHE:301246 Revenue

Hubei Hongyuan Pharmaceutical Technology had revenue of 703.53M CNY in the quarter ending March 31, 2026, with 62.31% growth. This brings the company's revenue in the last twelve months to 2.21B, up 24.26% year-over-year. In the year 2025, Hubei Hongyuan Pharmaceutical Technology had annual revenue of 1.94B with 9.53% growth.

• Revenue (ttm): 2.21B
• Revenue Growth: +24.26%
• P/S Ratio: 4.92
• Revenue / Employee: 978.54K
• Employees: 2,258
• Market Cap: 10.87B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.94B	168.75M	9.53%
Dec 31, 2024	1.77B	-284.16M	-13.83%
Dec 31, 2023	2.05B	-8.84M	-0.43%
Jan 1, 2023	2.06B	485.86M	30.79%
Jan 1, 2022	1.58B	274.92M	21.10%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 5, 2026

Data Sources Report a data error